Literature DB >> 22740849

Knockdown of proteolipid protein 2 or focal adhesion kinase with an artificial microRNA reduces growth and metastasis of B16BL6 melanoma cells.

Hiroki Ozawa1, Yoshiko Sonoda, Takaharu Suzuki, Naomi Yoshida-Hoshina, Megumi Funakoshi-Tago, Tadashi Kasahara.   

Abstract

Proteolipid protein 2 (PLP2) promotes the metastasis of B16F10 cells in an experimental metastasis model. However, the effect of PLP2 on spontaneous metastasis has yet to be demonstrated, and whether PLP2 may become a new therapeutic target for malignant tumors is as yet unknown. In this study, PLP2 or focal adhesion kinase (FAK) microRNA-based short hairpin RNAs (miRNAs) were used as target molecules to specifically reduce the expression of PLP2 or FAK in B16BL6 cells. In vitro, the knockdown of PLP2 or FAK significantly inhibited cell proliferation, adhesion, migration and invasion. In a spontaneous metastatic tumor model using a footpad injection, the knockdown of PLP2 or FAK markedly inhibited the proliferation of the primary tumor and prevented tumor cells from invading the popliteal lymph nodes. The results indicate that downregulation of PLP2 or FAK may improve outcomes of malignant tumor therapy.

Entities:  

Year:  2011        PMID: 22740849      PMCID: PMC3362453          DOI: 10.3892/ol.2011.422

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  10 in total

1.  Distribution of membrane anionic sites on B16 melanoma variants with differing lung colonising potential.

Authors:  A Raz; C Bucana; W McLellan; I J Fidler
Journal:  Nature       Date:  1980-03-27       Impact factor: 49.962

2.  FAK is the upstream signal protein of the phosphatidylinositol 3-kinase-Akt survival pathway in hydrogen peroxide-induced apoptosis of a human glioblastoma cell line.

Authors:  Y Sonoda; S Watanabe; Y Matsumoto; E Aizu-Yokota; T Kasahara
Journal:  J Biol Chem       Date:  1999-04-09       Impact factor: 5.157

Review 3.  Focal adhesion kinase signaling activities and their implications in the control of cell survival and motility.

Authors:  Steven K Hanks; Larisa Ryzhova; Nah-Young Shin; Jan Brábek
Journal:  Front Biosci       Date:  2003-05-01

Review 4.  Reprogramming metastatic tumour cells with embryonic microenvironments.

Authors:  Mary J C Hendrix; Elisabeth A Seftor; Richard E B Seftor; Jennifer Kasemeier-Kulesa; Paul M Kulesa; Lynne-Marie Postovit
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

5.  Polyethylenimine-complexed plasmid particles targeting focal adhesion kinase function as melanoma tumor therapeutics.

Authors:  Shufeng Li; Wei Dong; Yiwei Zong; Wu Yin; Guanghui Jin; Qingang Hu; Xiaofeng Huang; Wenhui Jiang; Zi-Chun Hua
Journal:  Mol Ther       Date:  2007-02-06       Impact factor: 11.454

6.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited.

Authors:  Isaiah J Fidler
Journal:  Nat Rev Cancer       Date:  2003-06       Impact factor: 60.716

Review 7.  Cancer spread and micrometastasis development: quantitative approaches for in vivo models.

Authors:  Ian C MacDonald; Alan C Groom; Ann F Chambers
Journal:  Bioessays       Date:  2002-10       Impact factor: 4.345

8.  PRL-3 siRNA inhibits the metastasis of B16-BL6 mouse melanoma cells in vitro and in vivo.

Authors:  Feng Qian; Yu-Pei Li; Xia Sheng; Zi-Chao Zhang; Ran Song; Wei Dong; Shao-Xian Cao; Zi-Chun Hua; Qiang Xu
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

9.  Mutation of Y925F in focal adhesion kinase (FAK) suppresses melanoma cell proliferation and metastasis.

Authors:  Tomonori Kaneda; Yoshiko Sonoda; Kumi Ando; Takaharu Suzuki; Yasuhiro Sasaki; Tomoyuki Oshio; Megumi Tago; Tadashi Kasahara
Journal:  Cancer Lett       Date:  2008-07-07       Impact factor: 8.679

10.  Proteolipid protein 2 is associated with melanoma metastasis.

Authors:  Yoshiko Sonoda; Masako Warita; Takaharu Suzuki; Hiroki Ozawa; Yusuke Fukuda; Megumi Funakoshi-Tago; Tadashi Kasahara
Journal:  Oncol Rep       Date:  2010-02       Impact factor: 3.906

  10 in total
  6 in total

1.  MiR-422a weakened breast cancer stem cells properties by targeting PLP2.

Authors:  Yanmei Zou; Yuandong Chen; Shuo Yao; Guangrui Deng; Dian Liu; Xun Yuan; Shunfang Liu; Jie Rao; Huihua Xiong; Xianglin Yuan; Shiying Yu; Feng Zhu; Yihua Wang; Hua Xiong
Journal:  Cancer Biol Ther       Date:  2018-03-30       Impact factor: 4.742

2.  Reduced expression of proteolipid protein 2 increases ER stress-induced apoptosis and autophagy in glioblastoma.

Authors:  Zichao Feng; Wenjing Zhou; Jiwei Wang; Qichao Qi; Mingzhi Han; Yang Kong; Yaotian Hu; Yulin Zhang; Anbin Chen; Bin Huang; Anjing Chen; Di Zhang; Wenjie Li; Qing Zhang; Rolf Bjerkvig; Jian Wang; Frits Thorsen; Xingang Li
Journal:  J Cell Mol Med       Date:  2019-11-28       Impact factor: 5.310

3.  Expression of miR-664-3p in Osteosarcoma and Its Effects on the Proliferation and Apoptosis of Osteosarcoma Cells.

Authors:  Ye Li; Jie Tang; Yong Hu; Yonghai Peng; Junwen Wang
Journal:  Iran J Public Health       Date:  2019-10       Impact factor: 1.429

4.  PLP2-derived peptide Rb4 triggers PARP-1-mediated necrotic death in murine melanoma cells.

Authors:  Vera S C Maia; Rodrigo Berzaghi; Denise C Arruda; Fabrício C Machado; Leticia L Loureiro; Pollyana M S Melo; Alice S Morais; Alexandre Budu; Luiz R Travassos
Journal:  Sci Rep       Date:  2022-02-21       Impact factor: 4.379

5.  E-Cadherin, NFATC3, and PLP2 Are Differentially Methylated in Multiple Cancers.

Authors:  Mary J Lotesto; Christopher J Wallace; Stacey L Raimondi
Journal:  Epigenet Insights       Date:  2020-10-20

6.  Loss of MiR-664 Expression Enhances Cutaneous Malignant Melanoma Proliferation by Upregulating PLP2.

Authors:  Zhenhua Ding; Sun Jian; Xuebiao Peng; Yimin Liu; Jianyu Wang; Li Zheng; Chengshan Ou; Yinghui Wang; Weixia Zeng; Meijuan Zhou
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.